YXYong Xu

Yong Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yong Xu has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The in-tissue molecular architecture of β-amyloid pathology in the mammalian brain

    by Conny Leistner, Martin Wilkinson, Ailidh Burgess, Megan Lovatt, Stanley Goodbody, Yong Xu, Susan Deuchars, Sheena E. Radford, Neil A. Ranson, René A. W. Frank

    Amyloid plaques composed of Aβ fibrils are a hallmark of Alzheimer’s disease (AD). However, the molecular architecture of amyloid plaques in the context of fresh mammalian brain tissue is unknown. Here, using cryogenic correlated light and electron tomography we report the in situ molecular architecture of Aβ fibrils in the AppNL-G-F familial AD mouse model containing the Arctic mutation and an atomic model of ex vivo purified Arctic Aβ fibrils. We show that in-tissue Aβ fibrils are arranged in a lattice or parallel bundles, and are interdigitated by subcellular compartments, extracellular vesicles, extracellular droplets and extracellular multilamellar bodies. The Arctic Aβ fibril differs significantly from an earlier AppNL-F fibril structure, indicating a striking effect of the Arctic mutation. These structural data also revealed an ensemble of additional fibrillar species, including thin protofilament-like rods and branched fibrils. Together, these results provide a structural model for the dense network architecture that characterises β-amyloid plaque pathology.


  • Open Access

    Controlling amyloid formation of intrinsically disordered proteins and peptides: slowing down or speeding up?

    by Yong Xu, Roberto Maya-Martinez, Sheena E Radford

    The pathological assembly of intrinsically disordered proteins/peptides (IDPs) into amyloid fibrils is associated with a range of human pathologies, including neurodegeneration, metabolic diseases and systemic amyloidosis. These debilitating disorders affect hundreds of millions of people worldwide, and the number of people affected is increasing sharply. However, the discovery of therapeutic agents has been immensely challenging largely because of (i) the diverse number of aggregation pathways and the multi-conformational and transient nature of the related proteins or peptides and (ii) the under-development of experimental pipelines for the identification of disease-modifying molecules and their mode-of-action. Here, we describe current approaches used in the search for small-molecule modulators able to control or arrest amyloid formation commencing from IDPs and review recently reported accelerators and inhibitors of amyloid formation for this class of proteins. We compare their targets, mode-of-action and effects on amyloid-associated cytotoxicity. Recent successes in the control of IDP-associated amyloid formation using small molecules highlight exciting possibilities for future intervention in protein-misfolding diseases, despite the challenges of targeting these highly dynamic precursors of amyloid assembly.


  • Open Access

    Single residue modulators of amyloid formation in the N-terminal P1-region of α-synuclein

    by Sabine M. Ulamec, Roberto Maya-Martinez, Emily J. Byrd, Katherine M. Dewison, Yong Xu, Leon F. Willis, Frank Sobott, George R. Heath, Patricija van Oosten Hawle, Vladimir L. Buchman, et al.

    Alpha-synuclein (αSyn) is a protein involved in neurodegenerative disorders including Parkinson’s disease. Amyloid formation of αSyn can be modulated by the ‘P1 region’ (residues 36-42). Here, mutational studies of P1 reveal that Y39A and S42A extend the lag-phase of αSyn amyloid formation in vitro and rescue amyloid-associated cytotoxicity in C. elegans. Additionally, L38I αSyn forms amyloid fibrils more rapidly than WT, L38A has no effect, but L38M does not form amyloid fibrils in vitro and protects from proteotoxicity. Swapping the sequence of the two residues that differ in the P1 region of the paralogue γSyn to those of αSyn did not enhance fibril formation for γSyn. Peptide binding experiments using NMR showed that P1 synergises with residues in the NAC and C-terminal regions to initiate aggregation. The remarkable specificity of the interactions that control αSyn amyloid formation, identifies this region as a potential target for therapeutics, despite their weak and transient nature.


  • Open Access

    The effect of mutation on an aggregation-prone protein: An in vivo, in vitro, and in silico analysis

    by N. Guthertz, R. van der Kant, R. M. Martinez, Y. Xu, C. H. Trinh, B. I. Iorga, F. Rousseau, J. Schymkowitz, D. J. Brockwell, S. E. Radford

    Aggregation of initially stably structured proteins is involved in more than 20 human amyloid diseases. Despite intense research, however, how this class of proteins assembles into amyloid fibrils remains poorly understood, principally because of the complex effects of amino acid substitutions on protein stability, solubility, and aggregation propensity. We address this question using β 2 -microglobulin (β 2 m) as a model system, focusing on D76N-β 2 m that is involved in hereditary amyloidosis. This amino acid substitution causes the aggregation-resilient wild-type protein to become highly aggregation prone in vitro, although the mechanism by which this occurs remained elusive. Here, we identify the residues key to protecting β 2 m from aggregation by coupling aggregation with antibiotic resistance in E. coli using a tripartite β-lactamase assay (TPBLA). By performing saturation mutagenesis at three different sites (D53X-, D76X-, and D98X-β 2 m) we show that residue 76 has a unique ability to drive β 2 m aggregation in vivo and in vitro. Using a randomly mutated D76N-β 2 m variant library, we show that all of the mutations found to improve protein behavior involve residues in a single aggregation-prone region (APR) (residues 60 to 66). Surprisingly, no correlation was found between protein stability and protein aggregation rate or yield, with several mutations in the APR decreasing aggregation without affecting stability. Together, the results demonstrate the power of the TPBLA to develop proteins that are resilient to aggregation and suggest a model for D76N-β 2 m aggregation involving the formation of long-range couplings between the APR and Asn76 in a nonnative state.


  • Open Access

    Tuning the rate of aggregation of hIAPP into amyloid using small-molecule modulators of assembly

    by Yong Xu, Roberto Maya-Martinez, Nicolas Guthertz, George R. Heath, Iain W. Manfield, Alexander L. Breeze, Frank Sobott, Richard Foster, Sheena E. Radford

    Human islet amyloid polypeptide (hIAPP) self-assembles into amyloid fibrils which deposit in pancreatic islets of type 2 diabetes (T2D) patients. Here, we applied chemical kinetics to study the mechanism of amyloid assembly of wild-type hIAPP and its more amyloidogenic natural variant S20G. We show that the aggregation of both peptides involves primary nucleation, secondary nucleation and elongation. We also report the discovery of two structurally distinct small-molecule modulators of hIAPP assembly, one delaying the aggregation of wt hIAPP, but not S20G; while the other enhances the rate of aggregation of both variants at substoichiometric concentrations. Investigation into the inhibition mechanism(s) using chemical kinetics, native mass spectrometry, fluorescence titration, SPR and NMR revealed that the inhibitor retards primary nucleation, secondary nucleation and elongation, by binding peptide monomers. By contrast, the accelerator predominantly interacts with species formed in the lag phase. These compounds represent useful chemical tools to study hIAPP aggregation and may serve as promising starting-points for the development of therapeutics for T2D.


  • Author Correction: Fibril structures of diabetes-related amylin variants reveal a basis for surface-templated assembly

    by Rodrigo Gallardo, Matthew G. Iadanza, Yong Xu, George R. Heath, Richard Foster, Sheena E. Radford, Neil A. Ranson

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.

  • Fibril structures of diabetes-related amylin variants reveal a basis for surface-templated assembly

    by Rodrigo Gallardo, Matthew G. Iadanza, Yong Xu, George R. Heath, Richard Foster, Sheena E. Radford, Neil A. Ranson

    Aggregation of the peptide hormone amylin into amyloid deposits is a pathological hallmark of type-2 diabetes (T2D). While no causal link between T2D and amyloid has been established, the S20G mutation in amylin is associated with early-onset T2D. Here we report cryo-EM structures of amyloid fibrils of wild-type human amylin and its S20G variant. The wild-type fibril structure, solved to 3.6-Å resolution, contains two protofilaments, each built from S-shaped subunits. S20G fibrils, by contrast, contain two major polymorphs. Their structures, solved at 3.9-Å and 4.0-Å resolution, respectively, share a common two-protofilament core that is distinct from the wild-type structure. Remarkably, one polymorph contains a third subunit with another, distinct, cross-β conformation. The presence of two different backbone conformations within the same fibril may explain the increased aggregation propensity of S20G, and illustrates a potential structural basis for surface-templated fibril assembly.


  • Pseudoruegeria marinistellae sp. nov., isolated from an unidentified starfish in Sanya, China

    by Yanfeng Zhang, Yong Xu, Wei Fang, Xiaotang Wang, Zemin Fang, Yazhong Xiao

    A taxonomic study was carried out on a Gram-stain negative, rod-shaped, non-flagellated, and facultatively anaerobic bacterial strain designated as strain SF-16T, which was isolated from an unidentified starfish in Sanya, China. Strain SF-16T was found to be 5.0–7.0 μm long, and oxidase and catalase positive. Cell growth was observed at pH 6.0–8.5 (optimum, 7.0–8.0), temperatures of 10–41 °C (optimum, 25–30 °C), and salinities of 0–12 % (optimum, 3.0–6.0 %). The predominant fatty acids (>20 %) were found to be C18:1 ω7c and/or C18:1 ω6c (summed feature 8). Ubiquinone 10 was identified as the predominant quinone for strain SF-16T. The polar lipids were identified as diphosphatidylglycerol, phosphatidylethanolamine, phosphatidylglycerol, two unidentified aminolipids, two unidentified lipids, and three unidentified phospholipids. The DNA G+C content of the genomic DNA of strain SF-16T was determined to be 63.0 mol%. Phylogenetic analysis based on the 16S rRNA gene showed that strain SF-16T belongs to the genus Pseudoruegeria and is closely related to Pseudoruegeria sabulilitoris GJMS-35T (98.42 % similarity). The ANI value between strain SF-16T and P. sabulilitoris GJMS-35T was found to be 74.98 %, and DNA–DNA hybridization value was 21.1 ± 2.3 % in silico and 57 % in vitro. Based on the low level of the genetic relatedness, phylogenetic and phenotypic data, a novel species Pseudoruegeria marinistellae sp. nov. is proposed. The type strain is SF-16T (=MCCC 1K01155T = KCTC 42910T).